GAINESVILLE – The three suspected West Nile virus cases discovered in Alachua County have been declared negative.

Paul Myers, Alachua County Health Department administrator, said one of the victims had symptoms consistent with West Nile.

“The confirmatory blood test indicated that one of the three individuals had been infected with the West Nile virus sometime in the past,” Myers said. “We just don’t know exactly when.”

The men had attempted to donate blood when the antibodies for West Nile were the discovered. Each of the men had been exposed to extensive time outside. One of the men had been infected with West Nile sometime in the past.

Alachua County is still under the Mosquito Born Illness advisory that took effect on Sept. 27, 2012.

West Nile symptoms include sudden onset of headache, fever, stiff neck. Symptoms can appear from 2 to 14 days from the first time of exposure.

The illness first appeared in Sentinel chickens. Myers mentioned at least one horse being infected with West Nile. Alachua County had one confirmed case of West Nile in 2003.

Myers said it is been a particularly bad year for West Nile virus.

“It goes back to the winter of 2011-2012. It was a very mild winter, the mosquito die off was not complete,” he said. “Tropical storm Debby came through and created overwhelming numbers of breeding places for mosquitos.”

Even with the cooler weather, Myers still urges residents to protect themselves

“It’s imminent that I will be lifting the Mosquito Borne Illness Advisory in consultation with the state health office,” he said.

Myers still recommends residents drain any standing water, wear long sleeves and check that window screens are in good repair to ensure protection from mosquitoes.

#     #     #

Email Bdupuy@

Alachuatoday.com

ALACHUA – It is likely that super sleuth Sherlock Holmes would have been amazed by modern crime scene forensics. And what better location is there than Alachua’s CSI Academy of Florida to showcase mock crime scenes for a film about Holmes. A London-based production company plans to feature the facility in a documentary. The CSI Academy, which is located in the Phoenix Industrial Park at 12787 U.S. Highway 441in Alachua, equips students with the tools necessary to enter into the field of crime scene investigation and to create more jobs within this field.

The film, produced by Love Productions, will focus on how Sherlock Holmes changed the world of modern crime-scene investigating.

The company filmed mock crime scenes and other footage at the 28,000-square-foot facility Wednesday and Thursday. The documentary will be released sometime in 2013.

Debbie Mongiardo, a member of the CSI Academy’s management team, said they expect a lot of exposure from the documentary.

“It’s definitely an opportunity for us,” she said. “It’s a big deal. It’s exciting.”

She said an employee from the production company contacted one of the academy’s instructors and asked about filming.

Mongiardo said the facility, which opened in September, has received inquiries from all over the country.

The academy offers a one-week basic course, primarily for law enforcement officers, and a 300-hour, seven-week course for anyone who is interested in a career in crime scene investigation.

The classes available include crime scene photography, ballistics, death investigations, blood evidence, fingerprint collection techniques, ballistics, sex crime investigation and more.

The programs are designed to prepare students to competently process crime scenes.

According to Department of Labor Statistics, CSI jobs are expected to grow by 19 percent from 2010 to 2020, about as fast as the average for all occupations. Competition for jobs will be strong because of substantial interest in forensic science.

Mongiardo said the seven-week course is $11,150, and that includes meals, textbooks and latent print kits. The academy sets up indoor and outdoor mock crime scenes to provide realistic training for students.

According to the Occupational Outlook Handbook published by the Bureau of Labor Statistics, detectives and criminal investigators earn an average annual salary of about $58,000, or about $28 per hour. A beginning crime scene investigation salary ranges between $34,000 and $45,000. A crime scene investigator salary can approach $100,000 with solid experience.

Additional information about the CSI Academy is available at http://www.csiacademyflorida.com.

#     #     #

Email astewart@

alachuatoday.com

ALACHUA – Motorists traveling through Alachua on U.S. Highway 441 may have noticed a change in speed limits near Progress Corporate Park.

Florida Department of Transportation (FDOT) recently ordered reduced speeds in the area as a result of a study the agency conducted. The changes come after what FDOT termed an “in-house request” to conduct a safety study of the U.S. 441 corridor in Alachua. The department determined that congestion in the area surrounding Progress Corporate Park, the Santa Fe College Perry Center and nearby State of Florida office park warranted adjustments in speed limits.

The 45 mile per hour speed limit zone was pushed eastward by about two-tenths of a mile, taking that zone to the edge of the County Road 2054 overpass. But likely more noticeable to motorists will be the extended 55 mile per hour zone, which was increased eastward to nearly a mile long. Under the new speed limit arraignment, the 65 mile per hour speed limit does not occur until the Calvary Baptist Church area.

Former Alachua Mayor Jean Calderwood had long been a proponent of speed limit reductions in that area of the U.S. 441 corridor. In previous years, Calderwood repeatedly requested that FDOT review the area and consider speed reductions due to a growing number of motorists entering and leaving the highway there.

#     #     #

Email editor@

alchuatoday.com

ALACHUA– Applied Genetic Technologies Corporation, (AGTC), a privately-held, clinical stage biotechnology company developing gene therapy products to treat rare retinal diseases, has secured $37.5 million in a Series B round of venture capital funding.

AGTC is a graduate company of the University of Florida Sid Martin Biotechnology Incubator located in Alachua’s Progress Corporate Park.

Alta Partner and S.R. One, Limited led the financing, with new investor Osage University Partners joining existing investors InterWest, Intersouth, and MedImmune Ventures in the round.

This brings AGTC’s total venture capital funding to almost $88 million. AGTC began life in the Sid Martin Biotechnology Incubator in 2000 and graduated in 2006.

The funding will allow AGTC to continue development of its Phase 2 program in Alpha-1 Antitrypsin Deficiency (Alpha-1) and initiate full development of potential treatments for Achromatopsia (ACHM) and X-Linked Rentinoschisis (XLRS).

ACHM is an inherited genetic condition that presents at birth with impaired visual acuity. Most patients are legally blind, lacking color discrimination and experiencing extreme light sensitivity, resulting in daytime blindness. ACHM is caused by mutations in a group of genes which make the cone cells concentrated in the central retina non-functional. There is no treatment for Achromatopsia, although deep red tinted spectacles or contact lenses can reduce symptoms of light sensitivity. Approximately 22,000 patients in the U.S. and Europe suffer from this disease.

AGTC’s potential treatment uses an adeno-associated virus (AAV), a safe, man-made virus that delivers healthy copies of the ACHM gene to the cells of the retina, replacing the defective copies of the gene. A single treatment is expected to halt the disease for several years, perhaps a lifetime. The AAV delivery system is successfully being used in clinical trials of Leber congenital amaurosis gene therapy that have restored vision in more than 50 adults and children who were virtually blind. Previous research has shown promising signs of efficacy in dog models of ACHM.

XLRS, an inherited genetic condition, is a leading cause of juvenile macular degeneration in males. It is caused by mutations in the RS1 gene, which results in the layers of the central retina splitting. Patients typically begin to experience progressive vision loss between the ages of 5 and 10. Other early symptoms include the inability to focus both eyes and roving, involuntary eye movements. No treatment for XLRS is currently available. Approximately 35,000 patients in the U.S. and Europe suffer from this disease. Previous research has shown promising signs of efficacy in rodent models of XLRS.

AGTC is focused on the research and development of novel therapeutics for patients with unmet medical needs utilizing AGTC’s proprietary, non-pathogenic adeno-associated virus (AAV) delivery system. The company has demonstrated that this system can be used to deliver a normal form of a gene in both animals and humans thus allowing their own body to produce sustained therapeutic levels of important biologics. The company’s most advanced programs in development are treatments for Alpha-1 antitrypsin deficiency (Alpha-1) a disease causing a progressive loss of lung function, and Leber’s Congenital Amaurosis, an inherited condition causing early blindness. Both utilize AGTC’s proprietary AAV system and production methods.

"We are strong believers in the business model of developing treatments for genetic disorders," said Ed Hurwitz, General Partner of Alta Partners. "Based on encouraging clinical results from AGTC and others, we concluded that a large set of genetically defined diseases could be cured using AGTC’s proprietary vectors and manufacturing technologies. The Series B financing is designed to move several of AGTC’s programs through proof of concept as well as to allow the company to leverage its manufacturing and development infrastructure with partners to accelerate a broad portfolio of curative products.”

#     #     #